InvestorsHub Logo
Followers 30
Posts 2774
Boards Moderated 4
Alias Born 10/24/2015

Re: None

Sunday, 04/17/2022 4:58:49 PM

Sunday, April 17, 2022 4:58:49 PM

Post# of 932
A PhI trial (NCT04217473) is assessing an 'armed' (encodes for hTNF-a and hIL-2) OV in R/R stage III/IV melanoma patients, who cannot be treated with curative intent and are eligible for TIL therapy. Patients receive TILT-123 intravenously and intratumorally, and TIL therapy without LD chemo or high-dose IL-2 https://www.businesswire.com/news/home/20220330005560/en/TILT-Biotherapeutics-Announces-Positive-Update-on-its-Phase-1-Immunotherapy-Clinical-Trials-in-Cancer